Despite the considerable variability in study duration, sample size, and diagnostic method, the SGLT2-i agents used resulted in improvements in non-invasive markers of steatosis or even fibrosis in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.